GLP-1 Agonist Neuroprotection Mechanism in PD

V2, Crosslink

🧫

GLP-1 Agonist Neuroprotection Mechanism in PD

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-glp1-ago

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# GLP-1 Agonist Neuroprotection Mechanism in PD ## Background and Rationale Parkinson's disease (PD) is characterized by progressive dopaminergic neurodegeneration in the substantia nigra, leading to motor dysfunction and cognitive decline. Recent preclinical evidence suggests that GLP-1 receptor agonists, originally developed for diabetes treatment, exhibit neuroprotective properties through multiple mechanisms including anti-inflammatory effects, mitochondrial stabilization, and promotion of n

METHODOLOGY NOTES

Phase 1 (Weeks 0-4): Recruit 120 early-stage PD patients (Hoehn-Yahr stages 1-2.5). Obtain informed consent and conduct baseline assessments including MDS-UPDRS, Montreal Cognitive Assessment, DaTscan SPECT imaging, and blood collection for biomarker analysis (inflammatory cytokines IL-1β, TNF-α, IL-6; oxidative stress markers 8-OHdG, MDA; GLP-1 pathway components). Phase 2 (Weeks 4-52): Randomize participants 1:1 to subcutaneous exenatide 2mg weekly or matched placebo. Conduct safety monitoring every 4 weeks with adverse event documentation and vital signs. Perform interim assessments at weeks 12, 24, and 36 including MDS-UPDRS Part III, cognitive testing, and biomarker sampling. Phase 3 (Week 52): Conduct comprehensive endpoint evaluation including repeat DaTscan SPECT, full clinical battery, and biomarker analysis. Perform CSF sampling in consenting participants (target n=60) for neuroinflammatory markers and α-synuclein species. Phase 4 (Weeks 52-56): Complete safety follow-up and

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.900314Z'}
summary	# GLP-1 Agonist Neuroprotection Mechanism in PD ## Background and Rationale Parkinson's disease (PD) is characterized by progressive dopaminergic neurodegeneration in the substantia nigra, leading to
entities	{'genes': ['GLP'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate GLP-1 Agonist Neuroprotection Mechanism in PD
methodology_notes	Phase 1 (Weeks 0-4): Recruit 120 early-stage PD patients (Hoehn-Yahr stages 1-2.5). Obtain informed consent and conduct baseline assessments including MDS-UPDRS, Montreal Cognitive Assessment, DaTscan
replication_status	replicated
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.900320', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

703

Outgoing

673

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GLP-1 Agonist Neuroprotection Mechanism in PD

derives from (16)

supports (33)

💬 Discussion